Regulatory filings from mid-August show that Farallon Capital Management sold its entire stake in Centessa Pharmaceuticals during the second quarter. This disclosure, which reflects trades made as of June 30, 2026, is a result of Centessa's acquisition by Eli Lilly and Company. [8]
The sale of Farallon's 4.81 million shares was part of the all-cash deal, which was announced in March 2026 and closed on June 24, 2026. [1, 7, 8] Eli Lilly acquired Centessa to gain its pipeline of sleep disorder drugs. [7, 10] Farallon's position was valued at approximately $191 million, and its exit was a consequence of the merger rather than a standalone investment decision.